HIV Incidence Rate

INDICATION

DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

Nearly all patients remained HIV-free with DESCOVY FOR PrEP1

DESCOVY FOR PrEP was noninferior to TRUVADA

  • HIV incidence rate of 0.16/100 PY vs 0.34/100 PY (IRR=0.47; CI: 0.19-1.15)
Percent of patients who remained HIV-free

  • Primary analysis: when 100% of patients reached Week 48 and ≥50% reached Week 96

Treatment outcomes were similar across subgroups of age, race, gender identity, and baseline TRUVADA use.

Seroconversions

IRR=incidence rate ratio; PY=person-years.